Is response rate relevant to the phase II trial design of targeted agents?

J Clin Oncol. 2008 Mar 10;26(8):1204-5. doi: 10.1200/JCO.2007.15.2827. Epub 2008 Feb 19.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / metabolism
  • Clinical Trials, Phase II as Topic
  • Endpoint Determination
  • Female
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Research Design

Substances

  • Biomarkers, Tumor